'Informed choice': Nestle CEO on the company's Aimmune Therapeutics acquisition

Mark Schneider, Nestle CEO, joins 'Closing Bell' to discuss the company's acquisition of peanut allergy treatment maker Aimmune and on consumer trends he's seeing.